Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Blood

Volumn 125, Issue 17, 2015, Pages 2689-2692

  Ranganathan, Parvathi ^a,b   Yu, Xueyan ^a,b   Santhanam, Ramasamy ^a,b   Hofstetter, Jessica ^a,b   Walker, Alison ^a,b   Walsh, Katherine ^a,b   Bhatnagar, Bhavana ^a,b   Klisovic, Rebecca ^a,b   Vasu, Sumithira ^a,b   Phelps, Mitch A ^c   Devine, Steven ^a,b   Shacham, Sharon ^d   Kauffman, Michael ^d   Marcucci, Guido ^a,b   Blum, William ^a,b   Garzon, Ramiro ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; DECITABINE; EXPORTIN 1; SELINEXOR; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; AZACITIDINE; CELL RECEPTOR; DNA METHYLTRANSFERASE; EXPORTIN 1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILEUKEMIC EFFECT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; LEUKEMIA CELL LINE; MONOTHERAPY; MOUSE; MOUSE MODEL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; DNA MODIFICATION METHYLASES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYDRAZINES; KARYOPHERINS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84928490666     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-607648     Document Type: Article

References (15)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907.
2. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172-1179.
3. Plass C, Oakes C, Blum W, Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol. 2008;35(4):378-387.
4. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473-7478.
5. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009;69(2):510-517.
6. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-2655.
7. Kanai M, Hanashiro K, Kim SH, et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol. 2007;9(10):1175-1183.
8. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009;65(1):153-159.
9. van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009;124(8):1829-1840.
10. Etchin J, Sun Q, Kentsis A, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 2013;27(1):66-74.
11. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765-1773.
12. Garzon R, Flinn I, Berdeja J, et al. A phase 1 dose escalation study of the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with relapsed / refractory acute myeloid leukemia (AML) [abstract]. Haematologica. 2014;99(s1):527. Abstract S1353.
13. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-446.
14. Schmelz K, Wagner M, Dörken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114(5):683-695.
15. Thépot S, Lainey E, Cluzeau T, et al. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle. 2011;10(14):2323-2330.